A total of @ patients with HBeAg-positive CHB were randomly divided into treatment groups for LDT monotherapy ( n = @ ; @ mg orally , once daily ) and LDT+ADV combination therapy ( n = @ ; LDT @ mg plus ADV @ mg orally , once daily ) .